PeppiLibrary

Cognitive

Semax peptide reference

Russian-developed nootropic peptide. BDNF/NGF upregulation. Intranasal.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Semax notes
Default dose label600 mcg
Preferred routeIntranasal
Frequency label1–2× daily
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Approved in Russia with clinical trial data; limited Western literature

Prescription medication (Russia); research chemical elsewhere

Route map

How records are usually labeled

1 Intranasal
2 SubQ

Alternate nostrils to avoid local irritation.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; powder is stable frozen.
After mixRefrigerate 2–8 °C; nasal spray bottles use within 14–30 days.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose 600 mcg
Route Intranasal
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Semax. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Semax is a synthetic heptapeptide analog of ACTH(4-10) developed at the Russian Academy of Sciences. It has been researched for cognitive enhancement, neuroprotection, and stroke recovery. Approved in Russia as a treatment for stroke, cognitive impairment, and optic nerve disorders. Typically administered intranasally for rapid CNS uptake.

Also known as: ACTH(4-10) analog, N-acetyl Semax (NA-Semax variant).

Cognitive enhancement (focus, memory)Stroke recovery (per Russian indication)Neuroprotection research

Mechanism and timing snapshot

Modulates BDNF and NGF expression in hippocampus and cortex; affects monoaminergic systems (dopamine, serotonin); resists peptidase degradation longer than native ACTH(4-10).

Onset label5 min
Catalog onset field, when available.
Half-life label24 min
Plasma half-life ~20–30 min; downstream BDNF effects persist 24+ hours
Duration label6 hr
Catalog duration field, when available.
intranasal Moderate (~60–70%)
subQ High
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose600 mcg
Catalog dose range250 mcg - 900 mcg
Default routeIntranasal
Frequency label1–2× daily
Best time labelMorning and early afternoon; avoid late evening (mildly stimulating).
Food noteNone.

Catalog protocol note

300–600 mcg intranasal 1–2× daily for 7–14 days; longer courses for stroke recovery per Russian protocols.

Routes and site notes

Available route labelsIntranasal, SubQ
Preferred route labelIntranasal
Common site labelsBoth nostrils, alternating
Site rotation noteAlternate nostrils to avoid local irritation.

Chemistry

SequenceMet-Glu-His-Phe-Pro-Gly-Pro
Amino acids7
Molecular formulaC37H51N9O10S
Molecular weight813.93 Da

Vial, reconstitution, and storage

Supply formPre-formulated nasal spray (Russian commercial) or lyophilized powder
Typical vial size5 mg
DiluentBacteriostatic water or saline
Diluent volume5 mL
Concentration note5 mg in 5 mL → 0.6 mL = 600 mcg per dose (depends on sprayer calibration).
Before reconstitutionRefrigerate 2–8 °C; powder is stable frozen.
After reconstitutionRefrigerate 2–8 °C; nasal spray bottles use within 14–30 days.
Reconstituted shelf life30 days
Light sensitiveNo
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Nasal irritation (intranasal)
  • Mild headache early in use
  • Slightly stimulating in some users
  • Insomnia if dosed late
  • Mild restlessness

Contraindications and warnings

  • Pregnancy
  • Severe psychiatric disorders without clinician oversight
  • Approved in Russia only; research-only elsewhere.

Other considerations

  • Subjective effects vary widely — some users report strong focus, others minimal.
  • Dose mornings only to avoid sleep disruption.

Evidence and regulatory context

Evidence levelApproved in Russia with clinical trial data; limited Western literature
FDA approvedNo
Regulatory statusPrescription medication (Russia); research chemical elsewhere
Prescription requiredYes
Approved countriesRussia

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteNot listed
Typical cycle label1–2
Typical break label1–2
Cycle guidanceShort courses are typical; effects on BDNF persist beyond the dosing window.

Tracking tips

  • Morning dosing only — late doses can disrupt sleep.
  • N-acetyl Semax variant has a longer half-life and is sometimes preferred.
  • Subjective effects are subtle compared to typical stimulants; assess over a 1–2 week course.

References

Track it in Peppi

Keep Semax records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Semax?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Semax?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Semax records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026